Illumina sees the light – or thinks it does
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Esmo 2020 – some backing for Beigene’s unusual combo approach
The company is one of very few to have studied combining PD-1 and PD-L1 blockade, an approach still in need of scientific validation.
Esmo 2020 – Lilly’s latecomer scores in early breast cancer
Verzenio looks set to move into a valuable adjuvant setting as Pfizer’s miss with Ibrance is laid bare.
Medtech
FDA tightens up digital health oversight
Software-enabled medical devices pose unique challenges to regulators, and the US agency is getting serious about meeting them.
Illumina sees the light – or thinks it does
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Company Events
Amgen and Astra hope to carve out a place in asthma
Pivotal data are expected soon on tezepelumab, Amgen and Astrazeneca's shot at non-eosinophilic asthma.
Go or no go? A quiet month ahead for US approval verdicts
A decision is due on Bristol’s new leukaemia project, while Mallinckrodt and Mesoblast await their fates after mixed panel meetings.
Bristol hopes to Tyk the psoriasis box
The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.
Interviews
Novo adds weight to its obesity goals
Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.
Healthineers’ Covid-19 antibody test spikes an interest in vaccines
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
Making sense of Covid-19 treatment approaches
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
Evaluate Omnium
Evaluate Omnium is the first and only solution on the market that provides a complete, dynamic view of development risk and commercial return, while also addressing the information gaps that lead to unproductive portfolio investments. The result is 4 times greater accuracy when predicting which Phase I assets will reach the market and a 21% accuracy improvement when predicting commercial potential for Phase I assets, compared to calculations made based on industry average benchmarks.